Note: This document contains side effect information about anidulafungin. Some of the dosage forms listed on this page may not apply to the brand name Eraxis.
Applies to anidulafungin: intravenous powder for solution
Along with its needed effects, anidulafungin (the active ingredient contained in Eraxis) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking anidulafungin:
Some side effects of anidulafungin may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Applies to anidulafungin: intravenous powder for injection
The most common side effects reported during studies in patients with candidemia and other Candida infections were hypokalemia, nausea, diarrhea, vomiting, pyrexia, and insomnia. Anidulafungin was discontinued in 11.5% of patients due to side effects. The most common side effects leading to discontinuation of anidulafungin (the active ingredient contained in Eraxis) were multi-organ failure and systemic Candida infection.
The most common side effects reported during a study in patients with esophageal candidiasis were diarrhea, pyrexia, anemia, headache, vomiting, nausea, and dyspepsia. Anidulafungin was discontinued in 9% of patients due to side effects. The most common side effect leading to discontinuation of anidulafungin was maculopapular rash.
Metabolic side effects have included hypokalemia (up to 25%), hypomagnesemia (12%), increased blood alkaline phosphatase (12%), hypoglycemia (7%), hyperglycemia (6%), hyperkalemia (6%), dehydration (6%), increased amylase (less than 2%), increased creatine phosphokinase (less than 2%), increased lipase (less than 2%), decreased potassium (less than 2%), decreased magnesium, hypercalcemia, and hypernatremia.
Gastrointestinal side effects have included nausea (up to 24%), diarrhea (up to 18%), vomiting (up to 18%), constipation (8%), dyspepsia (7%), abdominal pain (6%), oral candidiasis (5%), upper abdominal pain, and fecal incontinence.
To reduce occurrence of infusion-related side effects, the rate of infusion should not exceed 1.1 mg/minute.
Other side effects have included pyrexia (up to 18%), bacteremia (18%), peripheral edema (up to 11%), sepsis (7%), chest pain (5%), flushing (less than 2%), hot flushes (less than 2%), infusion-related reaction (less than 2%), rigors (less than 2%), clostridial infection (less than 2%), fungemia, candidiasis, multi-organ failure, and systemic Candida infection. Infusion-related side effects, possibly histamine-mediated, have included rash, urticaria, flushing, pruritus, bronchospasm, dyspnea, and hypotension.
Cardiovascular side effects have included hypotension (15%), hypertension (12%), deep vein thrombosis (10%), phlebitis, and electrocardiogram early transition. Atrial fibrillation, bundle branch block (right), sinus arrhythmia, superficial thrombophlebitis, electrocardiogram QT prolonged, and ventricular extrasystoles have been reported in less than 2% of patients.
Psychiatric side effects have included insomnia (15%), confusional state (8%), and depression (6%).
Genitourinary side effects have included urinary tract infection (15%).
Respiratory side effects have included dyspnea (12%), pleural effusion (10%), cough (up to 7%), pneumonia (6%), and respiratory distress (6%). Bronchospasm has been reported during postmarketing experience.
Hematologic side effects have included anemia (up to 9%), increased white blood cell (8%), thrombocythemia (6%), leukocytosis (5%), coagulopathy (less than 2%), thrombocytopenia (less than 2%), prothrombin time prolonged (less than 2%), neutropenia, leukopenia, and increased and decreased platelet count.
Nervous system side effects have included headache (8%), convulsion (less than 2%), and dizziness (less than 2%).
Hepatic side effects have included increased hepatic enzymes (5%), ALT, and AST. Increased gamma-glutamyltransferase, increased bilirubin, abnormal liver function tests, cholestasis, and hepatic necrosis have been reported in less than 2% of patients. Significant hepatic dysfunction, hepatitis, and hepatic failure have been reported.
Hypersensitivity side effects have included anaphylactic shock and anaphylactic reaction during postmarketing experience.
Dermatologic side effects have included decubitus ulcer (5%), rash, generalized pruritus, and maculopapular rash. Erythema, pruritus, increased sweating, urticaria, and angioneurotic edema have been reported in less than 2% of patients.
Renal side effects have included increased blood creatinine (5%) and urea (less than 2%).
Musculoskeletal side effects have included back pain (5%).
Ocular side effects have included eye pain, blurred vision, and visual disturbance in less than 2% of patients.
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Eraxis